GlassScriptPhysician profile
Tracy Ramsey
NPI 1164952073
$1,745.60
in general payments reported to CMS, 2019-2025
20 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $208 · 2022: $314 · 2023: $418 · 2024: $331 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $320.71 | 2021-2025 | |
| Novo Nordisk INC | $292.43 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $223.52 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $187.38 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $158.74 | 2022-2025 | |
| Amgen INC. | $116.98 | 2022-2025 | Evenity, Prolia, Otezla |
| Ironshore Pharmaceuticals INC. | $62.59 | 2022-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $62.44 | 2025 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.03 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.04 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $31.07 | 2021-2022 | |
| Daiichi Sankyo INC. | $28.68 | 2023 | Injectafer |
| Corium, LLC | $27.20 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $25.04 | 2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $21.61 | 2025 | Spravato |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $20.43 | 2025 | Aptima |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.55 | 2024 | Caplyta |
| Mylan Specialty L.P. | $17.42 | 2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $16.29 | 2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Ramsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.